Drug intelligence / Profile preview

KP-09S

Development stage: Preclinical
Lead developer: Kangpu Biopharmaceuticals
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

KP-09S is a novel degradable molecular glue developed by Kangpu Biopharmaceuticals. It functions as a cereblon (CRBN) modulator, specifically targeting the CRBN E3 ubiquitin ligase complex (CRL4-CRBN). By modulating this complex, KP-09S promotes the degradation of specific proteins involved in disease processes, particularly in neoplasms. The drug is currently in preclinical development and has shown potential for the treatment of cancers, especially relapsed or refractory malignancies[1][4].

Targets

CRBN (Cereblon)

Beyond the preview

Go deeper on KP-09S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP-09S.

Explore the full profile